Tag - Mackie

Markets

Analysts downgrade Correvio Pharma as FDA Adcom rejects Brinavess

Analysts for H.C. Wainwright, Mackie Research and Echelon Wealth Partners downgraded Correvio Pharma (NASDAQ:CORV) after the FDA Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against recommending approval...

December 11, 2019

Markets

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Mackie Research upgraded Theratechnologies (TSX:TH; NASDAQ:THTX) to “buy” from “hold” but maintained its price target at $6.50 (Canadian), saying the current share price represents a favorable risk-reward situation...

December 11, 2019

Markets

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Mackie Research Capital upgraded Knight Therapeutics (TSX:GUD) to “buy” from “hold” and raised its price target to $10.80 from $8.20 after Knight’s planned acquisition of Grupo Biotoscana for $369-million (Canadian)...

October 23, 2019

Markets

Mackie ups Acerus Pharma PT to 50 cents from 40 cents

Mackie Research raised its price target for Acerus Pharmaceuticals (TSX:ASP, OTCQB:ASPCF) to 50 cents from 40 cents, reflecting an amended agreement with Aytu Biosciences (NASDAQ:AYTU) that would move their partnership...

July 31, 2019

Markets

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

Mackie Research Capital lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $5.30 from $7.10 after the company lowered first quarter expectations on the back of weak Absorica sales. Analyst Andre Uddin...

April 24, 2018

Markets

Mackie starts Acerus Pharma at speculative buy; PT 50 cents

Mackie Research Capital initiated coverage of Acerus Pharmaceuticals (TSX:ASP) with a “speculative buy” rating and a 12-month target price of 50 cents. The stock closed at 26 cents on March 13. Acerus specializes in men...

March 14, 2018

Tag - Mackie

Analysts downgrade Correvio Pharma as FDA Adcom rejects Brinavess

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Mackie ups Acerus Pharma PT to 50 cents from 40 cents

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

Mackie starts Acerus Pharma at speculative buy; PT 50 cents

General

More